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Transfection efficiencya b s t r a c t
Non-viral gene therapy based on gene silencing with small interfering RNA (siRNA) has attracted great
interest over recent years. Among various types of cationic complexation agents, amino acid-based sur-
factants have been recently explored for nucleic acid delivery due to their low toxicity and high biocom-
patibility. Monoolein (MO), in turn, has been used as helper lipid in liposomal systems due to its ability to
form inverted nonbilayer structures that enhance fusogenicity, thus contributing to higher transfection
efficiency. In this work, we focused on the development of nanovectors for siRNA delivery based on three
gemini amino acid-based surfactants derived from serine — (12Ser)2N12, amine derivative;
(12Ser)2COO12, ester derivative; and (12Ser)2CON12, amide derivative — individually combined with
MO as helper lipid. The inclusion of MO in the cationic surfactant system influences the morphology
and size of the mixed aggregates. Furthermore, the gemini surfactant:MO systems showed the ability
to efficiently complex siRNA, forming stable lipoplexes, in some cases clearly depending on the MO con-
tent, without inducing significant levels of cytotoxicity. High levels of gene silencing were achieved in
C. Costa, I.S. Oliveira, João P.N. Silva et al. Journal of Colloid and Interface Science 584 (2021) 34–44comparison with a commercially available standard indicating that these gemini:MO systems are promis-
ing candidates as lipofection vectors for RNA interference (RNAi)-based therapies.
 2020 Elsevier Inc. All rights reserved.Fig. 1. Molecular structure of the amphiphiles used in this work. The gemini
surfactants A-C differ on the nature and location of the linkage between spacer and
serine-based headgroup: A, (12Ser)2N12, amine derivative; B, (12Ser)2COO12, ester
derivative; and C, (12Ser)2CON12, amide derivative. D is the helper lipid monoolein.1. Introduction
The fast development of nanoscience and nanotechnology over
the last decade has prompted the emergence of robust and effec-
tive nucleic acid delivery systems for gene therapy to prospectively
replace viral vectors [1–3]. The discovery of RNA interference
(RNAi), and subsequent findings of its mechanisms of action,
opened up exciting possibilities for its use in gene therapy, and
generated new perspectives for hard-to-treat diseases [4–6]. Small
RNAs are introduced into human, animal or plant cells, and activate
the RNA interference machinery to break down mRNA with a com-
plementary sequence. However, a major challenge to the use of
RNAi-based therapies is their efficient delivery through an appro-
priate vector to avoid rapid elimination by endogenous nucleases
[7–10]. Over the last years, much work has focused on the develop-
ment of effective vectors for small interfering RNA (siRNA) deliv-
ery, particularly liposomes and other types of colloidal
nanocarriers [11–15].
Gemini or dimeric surfactants, with two polar heads and two
hydrocarbon tails per molecule separated by a spacer group con-
nected at the level of the headgroups, have been subject of great
attention, both from fundamental [16,17] and application-
oriented perspectives [18,19]. This continuous interest results from
their unique physicochemical properties, which can be modified by
adjusting their structural elements, namely the polar headgroups,
hydrocarbon tails and covalent spacer [20–22]. Cationic gemini
surfactants, in particular, have been employed with the goal of
attaining more effectiveness for gene delivery [23–33]. Most
reports have focused on compounds with quaternary ammonium
headgroups and linear aliphatic tails, called bis-quats [31,33].
However, these surfactants exhibit relatively high levels of cyto-
toxicity, which limit their use in biomedical applications [34]. To
overcome this problem, gemini surfactants based on natural struc-
tural motifs such as sugars, amino acids and peptides have been
designed and synthesized [6,35–37]. These compounds combine
the efficiency of the gemini molecular structure with the biocom-
patibility of biomacromolecules, hence presenting enhanced
physico-chemical and biological profiles [38,39]. Several studies
have shown that the introduction of amino acid motifs in the struc-
ture of gemini amphiphiles promotes an increase in transfection
efficiency compared to conventional standards such as Lipofec-
tamine [23,40–42].
Previous work by our group on the synthesis and characteriza-
tion of amino acid-derived single-tailed surfactants derived from
serine, tyrosine and 4-hydroxyproline has shown that the optimal
toxicological profile and most interesting physicochemical proper-
ties are obtained with the serine derivatives [43–45]. These results
lead us to the synthesis of cationic serine-based gemini surfactants,
exploring the multifunctionality of the serine headgroup, by
changing the spacer chain length as well as the nature of the bond
linking the spacer to the amino acid residue (as can be seen in
Fig. 1A–C) [46]. These novel surfactants displayed enhanced inter-
facial properties relative to homologous bis-quats [40,46,47], thus
allowing the use of lower amounts of compound to achieve the
same therapeutic effect, which is of particular interest for biomed-
ical applications [48].
The inclusion of helper lipids in liposomal formulations is one of
the possible strategies to potentiate transfection efficiency of35cationic surfactants by improving both the system’s stability in
physiological conditions and the endosomal escape ability
[49,50]. Recently, monoolein (MO) has been used as an efficient
helper lipid in liposomal systems for plasmidic DNA (pDNA) and
siRNA delivery [51–54]. MO is a neutral single-tailed unsaturated
lipid (Fig. 1D) that is known to self-assemble in water into non-
bilayer reverse structures, namely the inverted cubic phases Ia3d
and Pn3m [55,56]. In mixtures, MO is not only capable to fluidize
and stabilize the liposomal structures, but can also form reverse
cubic or hexagonal phases [11,57], known to enhance fusogenicity,
thus contributing to a higher transfection efficiency of MO-
containing lipoplexes [51–54].
The aim of this work was to develop nanovectors for therapeu-
tic siRNA delivery based on serine-derived gemini surfactants com-
bined with MO as helper lipid and to investigate the role of
chemical differences in the polar headgroup. All the surfactants
contain a 12-carbon alkyl chain linked to the nitrogen atom of
the amino acid and a 12-carbon spacer, connecting the two mono-
meric entities through their headgroups. They differ in the nature
of the spacer linkage, as shown in Fig. 1A to 1C; (12Ser)2N12 is
an amine derivative (A); (12Ser)2COO12, an ester derivative (B)
and (12Ser)2CON12, an amide derivative (C). The amine derivative
is a micelle-forming surfactant, while the ester and amide ones
form bilayer structures, namely vesicles at low concentration
[12]. Herein, we start by showing the cytotoxicity profiles of the
gemini-MO lipoplexes as well as their ability to effectively deliver
their load and silence a target gene. Given the interesting transfec-
tion results obtained, and in order to gain further insight, we then
proceeded to the characterization of shape, size and charge of the
mixed gemini:MO aggregates (containing varying content of the
helper lipid) and of the lipoplexes formed with different gemini:
RNA charge ratios, CR (+/-), in an effort to withdraw structure–ac-
tivity relationships.
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2.1. Materials
Serine derivatives O-tert-butyl L-serine, H-Ser(tBu)–OH (>99%)
and O-tert-butyl L-serine methyl ester hydrochloride, H-Ser(tBu)-
OMe.HCl (>99%) and the coupling agents benzotriazol-1-yloxy-tri
pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and O-
(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluorobo-
rate (TBTU) were purchased from Bachem. Solvents (p.a. quality)
and other chemicals, including 3-(4,5-dimethyl-2-thiazolyl)-2,5-d
iphenyl-2H-tetrazolium bromide (MTT), were obtained from
Sigma-Aldrich. Thin layer chromatography (TLC) aluminum foil
plates covered with silica 60 F254 (0.25 mm) and silica-gel 60
(70–230 mesh ASTM) for preparative column chromatography
were from Merck and SDS, respectively. The fluorescent lipid
rhodamine-phosphatidylethanolamine (kexc = 545 nm; kem = 576-
nm) and the heat-inactivated fetal bovine serum (FBS) were
acquired from Invitrogen. The transfection reagent Lipofec-
tamineRNAiMAX and the Quant-iTTM RiboGreen RNA assay kit
were obtained from Life Technologies. siRNA targeting the
enhanced green fluorescent protein (sieGFP) and a siRNA negative
control duplex (siCONTROL), with HPLC purification, were pur-
chased from Integrated DNA Technologies. The compositions are:
sieGFP: sense strand = 50-CAAGCUGACCCUGAAGUUdTdT-30; anti-
sense strand = 50-AACUUCAGGGUCAGCUUGdTdT-30; siCONTROL:
sense strand = 50-(50UGCGCUACGAUCGACGAUdTdT30); antisense
strand = 50-AUCGUCGAUCGUAGCGCAdTdT-30.
Monoolein (1-monooleoyl-rac-glycerol), 99% purity, was pur-
chased from Sigma-Aldrich. The serine-derived surfactants shown
in Fig. 1, A – dodecamethylene 1,12-bis{N-(dodecyl)-N-[(1S)-(2-h
ydroxy-1-methyloxycarbonyl)ethyl]-N-(methyl)ammonium} bis
(trifluoroacetate), B – O,O’-dodecane-1,12-diyl-bis{N-[(1S)-(1-
oxycarbonyl-2-hydroxy)ethyl]-N-dodecyl-N,N-dimethyl ammo-
nium} bis(trifluoroacetate) and C A N’, N’’-dodecane-1,12-diyl-bis
{N-[(1S)-(1-carbamoyl-2-hydroxyethyl]-N-dodecyl-N,N-dimethyl
ammonium} bis(trifluoroacetate), were synthesized according to a
previous report [46], where details on the synthetic procedures,
purification, and purity data (NMR, high resolution mass spectrom-
etry and surface tension) are available.
2.2. Methods
2.2.1. Sample preparation
Mixtures with different gemini surfactant:MO molar ratios,
namely (1:0), (4:1), (2:1), (1:1), (1:2) and (1:4), were prepared by
thin lipid film hydration. Briefly, defined volumes of each serine
derivative and MO stock solutions (both 20 mM in ethanol) were
mixed and the solvent removed under vacuum using a rotary evap-
orator, at 60 C for 45 min. The dried films were then hydrated with
ultrapure (Milli-Q) water at 40 C for 30 min, to a final amphiphile
concentration of 1 mM or 5 mM.
2.2.2. Preparation of siRNA-lipoplexes
Lipoplexes were prepared at 25 C by adding defined aliquots of
1 mM aqueous solutions of the gemini:MO mixtures (for all molar
ratios studied) to 10 mL of siRNA solution (10 mgmL1), to obtain
surfactant/siRNA CRs ranging from 0.5 to 20. The surfactant-to-
siRNA charge ratio, CR (+/-), is defined as:
CR þ=ð Þ ¼ 2 gemini surfactant½ ½siRNA phosphate groups ð1Þ
since each gemini molecule carries two positive charges. The lipo-
plexes were incubated at room temperature, under vortex stirring,
for 30 s, and then diluted with ultrapure water to a final siRNA con-36centration of 10 ngmL1. The samples were allowed to rest for one
hour before use.
2.2.3. Dynamic light scattering (DLS)
The size (mean diameter, <DH>), and zeta (f) potential of the
aggregates formed by the neat surfactants, the gemini:MO mix-
tures as well as siRNA-lipoplexes were measured with a Malvern
ZetaSizer Nano ZS, at 25 C. Disposable polystyrene cuvettes for
size measurements and U-shaped zeta potential cuvettes were
used. Both for DLS and zeta potential measurements a minimum
of 5 repeats per sample were performed. In DLS, the autocorrela-
tion function of the scattered light was fitted with the Zetasizer
Software v7.12 using different algorithms [58,59]: for the lipo-
plexes, the cumulants analysis algorithm was used to obtain the
mean size (z-average) and polydispersity index, as the samples
presented a unimodal, low polydispersity distribution; for the
gemini:MO aggregates, given the multimodal or polydisperse uni-
modal character of the distributions, a non-negative least squares
(NNLS) algorithm was used. The results are presented in scattered
intensity distribution data. For the zeta potential measurements,
the electrophoretic mobility, l, was measured using a combination
of electrophoresis and laser Doppler velocimetry techniques, and
the f-potential was calculated from l using the Henry equation,
with a dielectric constant of 78.5, a medium viscosity of 0.89 cP,
and a f(ja) function value of 1.5 (Smoluchowsky approximation).
2.2.4. Light microscopy
Light micrographs of serine-based surfactant: MO formulations
were obtained with an Olympus BX51 microscope, equipped with
Differential Interface Contrast (DIC). The images were obtained
with a DP71 digital video-camera and processed using the cellA
software from the manufacturer.
2.2.5. Cryo-transmission electron microscopy (Cryo-TEM)
Cryo-TEM was used for microstructure studies of lipoplexes.
The samples were prepared in an automatic plunge freezing from
Leica (Leica EM GP). A drop of the solution was placed on TEM
grids, the excess of solution was blotted to create a thin film over
the grid which was rapidly plunged into liquid ethane at its freez-
ing point. After the vitrification process, the samples were trans-
ferred, using a Gatan cryo holder, to the electron microscope,
JEOL JEM-2011, and the images were recorded with a CCD GATAN
895 USC 4000 camera.
2.2.6. Cells lines and culture conditions
Human Embryonic Kidney Cells (HEK293T; ATCC, USA), wild
type, or stably expressing enhanced green fluorescent protein
(HEK293eGFP; ECACC, UK) were grown in Dulbecco’s minimal
essential medium (DMEM), supplemented with 10% heat inacti-
vated fetal bovine serum (FBS), 1% penicillin–streptomycin, 1% L-
glutamine and 1% sodium pyruvate (supplemented with 2 mg/mL
puromycin) in a humidified incubator (5% CO2, 37 C). Cells were
subcultured every 2 days using 0.05% Trypsin-EDTA solution in
order to maintain subconfluency.
2.2.7. MTT cytotoxicity assay
The percentage of viable cells after incubation with gemini:MO
aggregates was determined by the MTT assay, which evaluates
metabolic activity. HEK293T cells were seeded into 96-well culture
plates at a cell density of 1.5  104 cells per well in complete cell
culture medium. Before the addition of the aggregates, the culture
medium was removed and replaced by 100 lL of fresh culture
medium. Defined aliquots of the testing samples (pre-sterilized
by filtration through a membrane filter with a pore diameter of
450 nm; 100 lgmL1) were then added to each well to achieve
final surfactant concentrations of 10, 25, 50 and 100 mM. During
Table 1
The values of IC50 determined by MTT assay in HEK 293T cell line upon exposure to
aqueous mixtures of the serine-based surfactants and MO at varying cationic
surfactant/MO molar ratios. For each system, the total surfactant/MO concentration






1:0 >100 >100 18
4:1 100 >100 18
2:1 75 39 18
1:1 24 35 18
1:2 33 34 28
1:4 63 29 21
* Typical uncertainty: ±10%.
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negative (cells in the presence of 100 lL DMSO) controls were pre-
pared. Cell viability was determined after 48 h according to manu-
facturer’s instructions.
2.2.8. siRNA complexation efficiency
The complexation efficiency of siRNA was determined using the
RiboGreen reagent according to the manufacturer’s instructions.
Briefly, 200 lL of serine-based aggregates were mixed with
100 lL of a RiboGreen solution (1:2000 in TE buffer) in a 96-well
culture plate. After 5 min of incubation at room temperature, the
fluorescence was measured in a Fluoroskan AscentTM FL Microplate
Fluorometer and Luminometer (Thermo scientific) using an excita-
tion/emission filter pair of 485/538 nm.
2.2.9. eGFP silencing
The eGFP silencing was evaluated and quantified by flow
cytometry. The siRNA-lipoplexes at CR (+/-) = 5 and 10 were pre-
pared with 30 nM of siRNA eGFP-targeting siRNA (sieGFP), ensur-
ing that all systems were above the critical aggregation
concentration of the gemini:MO mixture. HEK293eGFP cells were
seeded into 24-well culture plates at a cell density of 1.0 105 cells
per well, in complete cell culture medium, and incubated overnight
at 37 C and in 5% CO2. Then, the cell culture mediumwas removed
and replaced by a fresh medium containing 60 mL of the siRNA-
lipoplexes solution. LipofectamineRNAiMAX lipoplexes contain-
ing sieGFP, prepared according to procedures described by the sup-
plier, were used as positive control.
After 48 h of incubation, cells were analyzed on an EC800 Flow
Cytometry Analyzer (Sony Biotechnology Inc., Champaign, IL, USA).
To exclude debris from the analysis, the discriminant was set to the
forward scatter of the channel in the linear-peak mode. eGFP was
excited by a diode blue laser (488 nm) and the green autofluores-
cence of cells expressing eGFP was detected using a 530/50 nm
bandpass filter in the FL1 channel. Fluorescence signal was ampli-
fied with the logarithmic mode. A sample volume of 150 mL was
analyzed at a flow rate of 60 mLmin1. Total events of 15,000–
25,000 cells were counted. Every sample was run in triplicate for
reproducibility of the experiment. Analysis of data was performed
on the EC800 software version 1.3.6. (Sony Biotechnology Inc.,
Champaign, IL, USA).3. Results and discussion
3.1. Cytotoxicity of gemini/monoolein systems
The characterization of the cytotoxicity profile of novel
nanovectors is particularly relevant for the development of safe
biomedical nanodevices. The results for cytotoxicity studies ini-
tially performed for the gemini/MOmixtures with varying MO con-
tent can be seen in Table 1, where the IC50 (minimum
concentration to promote 50% decrease in cell viability) values
are shown (see also supplementary data, Fig. S1). Several trends
can be observed. First, the inclusion of MO has different effects
depending on the gemini type: for the amine, MO induces higher
cytotoxicity compared to the neat surfactant, but the dependence
is non-monotonic, achieving lowest IC50 at equimolarity (Table 1);
for the ester, MO induces a moderate but steady increase in cyto-
toxicity; for the amide, the effect of increasing MO is practically
null, with a slight decrease in cytotoxicity at high MO contents.
Secondly, if we compare the systems at highest MO content
(1:4 molar ratio), then the order of increasing cytotoxicity is
amine < ester < amide. Thirdly and most importantly, all formula-
tions induce low or no cytotoxicity (cell viability higher than 70%
according to International Standards Organization guidelines) at37concentrations below ~ 20 mM. As the physiological concentrations
of surfactant/lipid mixture necessary for transfection are typically
below 20 mM, it can be concluded that these vectors are not cyto-
toxic for the useful concentration range needed.
3.2. Transfection efficiency of gemini/monoolein/siRNA systems
HEK293eGFP cells constitutively overexpress eGFP. Therefore,
transfecting siRNA that silences the respective gene, expressed in
high levels in these cells, offers a straightforward way to evaluate
the efficacy of a novel transfection system. Commercially available
Lipofectamine developed for siRNA delivery was chosen as the
standard, and all the results obtained in the flow cytometry analy-
sis are expressed in relation to this transfection control, as % of
HEK293eGFP cells not expressing eGFP after 48 h incubation with
the different systems (Fig. 2). CRs (+/-) of 5 and 10 were chosen for
all systems (see further Section 3.4) to encapsulate 30 nM siRNA,
necessary for efficient gene silencing. The total gemini/MO concen-
trations were maintained below 18 mM (i.e. below the IC50 of any
mixture, Table 1).
The data presented in Fig. 2 reveal striking differences in trans-
fection efficiency depending on the content of MO and, in two of
the systems, on the CR (+/-). A clear trend is that lipoplexes with
MO generally lead to better eGFP gene silencing efficiency com-
pared to those with gemini surfactant alone. The (12Ser)2N12:
MO system shows an efficiency that increases gradually with
increasing MO present, irrespective of the CR (+/-) used. However,
the (12Ser)2COO12:MO and (12Ser)2CON12:MO systems behave
differently: (i) they transfect HEK293eGFP cells more efficiently
at high CR (+/-); (ii) at CR (+/-) = 10, increasing MO content leads
to a moderate increase in transfection efficiency for the ester, but
for the amide the variation seems to be non-monotonic with a peak
at (1:1) gemini/MO molar ratio; (iii) at CR (+/-) = 5, increasing MO
content has no significant effect in transfection efficiency, with the
exception of the amide system, at (1:4) ratio.
These results clearly point to a complex dependence of the
transfection ability on the composition of the systems, namely
MO content and CR (+/-). Since the reasons behind this behavior
could be, at least partially, related to the different structures that
may form depending on the type of serine-derived gemini con-
stituent, this hypothesis prompted us to a careful and detailed
structural characterization of initial gemini/MO aggregates and
derived lipoplexes for the three systems studied.
3.3. Characterization of the initial gemini/monoolein aggregates
The gemini surfactants studied in this work are soluble in water
at 25 C. However, they display a distinct self-aggregation behavior
[12]. The amine derivative forms micelles as the first aggregate,
Fig. 2. Evaluation of eGFP gene silencing in HEK293eGFP cells, by flow cytometry, after 48 h of incubation with the different lipoplex systems tested, encapsulating anti-GFP
siRNA at gemini-to-RNA charge ratio, CR (+/-), of 5 and 10, in comparison with transfection with Lipofectamine RNAiMAX: top left, (12Ser)2N12:MO system; top right,
(12Ser)2COO12:MO system; bottom, (12Ser)2CON12:MO system. The molar ratio of cationic gemini surfactant to MO in the lipoplexes was varied as (1:0,) (4:1), (2:1), (1:1),
(1:2) and (1:4).
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tants, forming large, polydisperse vesicles at low concentration.
The incorporation of MO into these systems results in marked
effects on particle size and polydispersity (DLS data), as can be fol-
lowed in Table 2 (see also supplementary data, Fig. S2A).
Surfactant (12Ser)2N12 alone in solution forms small micelles
which is the result of having a critical packing parameter (as orig-
inally defined by Israelachvili et al) [60], Ps, of about 1/3 [12]. The
(12Ser)2N12:MO system presents a bimodal distribution between
gemini:MO (4:1) up to (1:1), comprising a minor population of
ca. 2.5 nm aggregates, consistent with micelles, and a major popu-
lation of aggregates of <DH> in the range 220–280 nm. Video-
enhanced light microscopy (VELM) imaging (Fig. 3-c1) shows that
this population consists of vesicles, which are observed for the
entire range of (12Ser)2N12:MO ratios covered. The observed irreg-
ular (and non-obvious) variation in frequency of the micellar pop-
ulation with MO content could be explained if the samples have
not yet attained equilibrium composition. When there is excess
MO, (1:2) and (1:4) ratios, the micelles seemingly vanish and only
vesicles are present. An explanation for the observed effect of MO
addition is the increase in the average packing parameter of the
amphiphile system due to the bulky nature of MO, Ps > 1 [11], lead-
ing eventually to vesicles as the preferred aggregate structure (Ps 
1). Further evidence for the effect of MO in inducing bilayer phases,
namely lamellar liquid crystals, is also found in phase scanning38experiments of gemini/MO mixtures at high concentration (see
supplementary data, Fig. S3).
Surfactants (12Ser)2COO12 and (12Ser)2CON12 dispersed alone
in water form very large and polydisperse vesicles, as illustrated in
Fig. 3-a2 for the amide derivative. For (12Ser)2COO12, increasing
content of MO leads to the formation of smaller and less polydis-
perse vesicles in general, with a changeover from a bimodal to
monomodal distribution at (1:2) and (1:4) ratios (Table 2). For
(12Ser)2CON12, the trend is qualitatively similar, with two differ-
ences: monomodal size distributions appear between (2:1) and
(1:2), and at maximum content of MO, (1:4), a bimodal distribution
reappears, indicating that for the amide headgroup surfactant the
packing interactions with MO are slightly different. Fig. 3-b2 and
c2, for the amide:MO system at (1:1) and (1:4), illustrate that
MO has indeed the effect of decreasing the mean size of the aggre-
gates while maintaining the vesicle structure. We posit that the
general reduction in vesicle size induced by MO in the ester and
amide systems could be attributed to the fact that MO, having
Ps > 1, and hence propensity to form negatively curved surfaces,
may tend to reside preferentially in the inner monolayer of the
vesicles, stabilizing aggregates of overall higher mean spontaneous
curvature (i.e. lower <DH> ). Phase scanning experiments further
support that inclusion of MO preserves bilayer aggregates, as
shown from the formation of lamellar liquid crystals (supplemen-
tary data, Fig. S3).
Fig. 3. Video-enhanced light microscopy imaging of the gemini/MO aggregates and derived lipoplexes, for the amine and amide gemini. The upper row micrographs, c1, a2,
b2 and c2 show (12Ser)2N12/MO and (12Ser)2CON12/MO aggregates at total concentration of 5 mM, and varying gemini:MO molar ratio. In all cases, vesicle structures are
observed with different size ranges. The lower row micrographs illustrate the lipoplexes obtained from the upper aggregates by adding siRNA at CR (+/-) = 5. Lipoplexes C1,
A2, B2 and C2 are also presented below in Fig. 5, under cryo-TEM imaging, providing finer structural details.
Table 2
Mean hydrodynamic diameter (<DH> ± s.d.) and population frequency from DLS intensity distribution data, and zeta-potential (f-potential ± s.d.) values, for the aggregates formed
by surfactants (12Ser)2N12, (12Ser)2COO12 and (12Ser)2CON12 and MO at 1 mM total concentration and varying gemini:MO molar ratio (24 h after preparation).
gemini:MO molar ratio Population A Population B
<DH>/nm frequency/% <DH>/nm frequency/% f-potential/mV
(12Ser)2N12:MO
1:0 * * +63 ± 2
4:1 220 ± 17 88 2.4 ± 0.8 12 +59 ± 2
2:1 278 ± 53 66 2.6 ± 0.3 34 +59 ± 2
1:1 280 ± 27 84 2.5 ± 0.1 16 +54 ± 4
1:2 243 ± 58 100 – +61 ± 2
1:4 401 ± 42 100 – +61 ± 1
(12Ser)2COO12:MO
1:0 157 ± 40 12 1467 ± 73 88 +61 ± 3
4:1 197 ± 86 70 454 ± 15 30 +61 ± 2
2:1 226 ± 68 71 514 ± 53 29 +61 ± 2
1:1 146 ± 44 40 469 ± 54 60 +61 ± 2
1:2 245 ± 57 100 – – +65 ± 1
1:4 349 ± 49 100 – – +67 ± 2
(12Ser)2CON12:MO
1:0 179 ± 35 9 1147 ± 54 91 +67 ± 3
4:1 167 ± 12 58 989 ± 182 42 +64 ± 4
2:1 233 ± 92 100 – – +60 ± 2
1:1 216 ± 19 100 – – +60 ± 2
1:2 192 ± 2 100 – – +71 ± 1
1:4 132 ± 24 38 710 ± 104 62 +78 ± 1
*Not measurable (small micelles present).
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kinetic stability of a colloidal dispersion. Dispersions with |f-pote
ntial|  40 mV have good or excellent stability while dispersions
with |f-potential| < 30 mV have incipient stability and tend to floc-
culate or coagulate. All the studied systems present f-potential val-
ues above 54 mV (Table 2) indicating excellent colloidal stability
for the aggregates. In basically all the systems, increasing MO con-
tent does not seem to have a significant effect on the surface
charge of the aggregates, with the highest zeta potential achieved
at gemini:MO (1:4) for the ester and amide systems. Taken alto-
gether, these observations seem to be consistent with the hypoth-
esis presented above on a preferential distribution of MO in the
inner layer of vesicles.39Another significant observation is that the size of the mixed
gemini/MO aggregates for all 3 systems tested remains essentially
constant over a tested period of 60 days, irrespective of MO content
(see supplementary data, Fig. S4). This indicates that MO inclusion
does not hinder the stability of the aggregates over time (likely col-
loidal kinetic stability rather than thermodynamic stability), and
could also be a consequence of the high values of zeta potential
displayed.
3.4. Gemini/monoolein/siRNA lipoplex characterization
The study of lipoplex formation and structure by monitoring
both size and f-potential provides important clues on the driving
Fig. 4. (A) Mean diameter and (B) mean zeta potential for gemini/monoolein (MO)/siRNA lipoplexes as a function of the gemini/siRNA charge ratio, CR (+/-). The total
gemini + MO concentration is 1 mM and the gemini/MO molar ratio in the lipoplexes varies between (1:0) to (1:4). For every point in the plots the error bar is ±5%.
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fection efficiency. Preliminary light microscopy studies, as illus-
trated in Fig. 3C1 and Fig. 3A2-C2 for CR (+/-) = 5, clearly showed
that lipoplex formation is accompanied by a considerable reduc-
tion in size compared to the initial aggregates and suggest the
presence of spheroidal vesicles aggregates in Brownian motion. A
more in-depth characterization was performed by DLS, zeta poten-
tial measurements (Fig. 4) and cryo-TEM imaging (Fig. 5).
DLS size and zeta potential data are shown in Fig. 4(A) and (B),
respectively, with CR (+/-) varying between 0.5 and 20 for each
gemini/MO molar ratio (see also supplementary data, Fig. S2B).
Fig. 4(A) shows that beyond the observed f-potential neutraliza-
tion point, i.e. roughly for CR (+/-)  2, most of the lipoplexes have
a mean diameter around 100–250 nm. It is also observed that
around CR (+/-) = 1, lipoplexes have in some cases very large sizes
(>500 nm), and that high CR (+/-) values (20) seem to also cause
an increase in the size of the lipoplexes up to 600 nm.40The f-potential variation, Fig. 4(B), indicates that the negative
charge of siRNA phosphates is neutralized by the increasing
amount of cationic surfactant, as CR (+/-) increases. The (12Ser)2-
N12:MO lipoplexes display a somewhat complex profile, highly
dependent on the MO content in the mixture. Lipoplexes with
(12Ser)2N12/MO molar ratio of (1:0) and (4:1), that is with low
MO content, display very low f-potential until CR (+/-)  7.5, while
the others reach the neutralization point at CR (+/-)  2.5, indicat-
ing that a higher MO content, (2:1) to (1:4), facilitates the process
of siRNA complexation. In contrast, the (12Ser)2COO12:MO and
(12Ser)2CON12:MO lipoplexes evolve from negatively to positively
charged at CR (+/-) between 1 and 2, as could be reasonably
expected. For CR (+/-) > 4 onwards, the f-potential levels off at ~
+40 mV, suggesting the stabilization of the lipoplex structure.
Overall, at CR (+/-) = 5 and 10, all systems have formed stable lipo-
plexes, which were then deemed suitable for the cell transfection
evaluation already shown above.
Fig. 5. Cryo-TEM imaging of the lipoplexes formed by the (12Ser)2N12:MO (A1-C’1) and (12Ser)2CON12:MO (A2-C’2) systems with fixed CR (+/-) = 5; lipoplexes have
different gemini:MO molar ratios: (1:0) for A1 and A2; (1:1) for B1 and B2; (1:4) for C1, C’1, C2 and C’2.
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phology of the lipoplexes, cryo-TEM imaging was performed
(Fig. 5). The lipoplexes with gemini:MO ratio of (1:0), (1:1) and
(1:4), at fixed CR (+/-) = 5, were chosen, and the amine and amide
surfactants were considered representative for these studies, given
the similarity in structures typically observed between the amide
and ester derivatives.
In Fig. 5A1, one observes for the neat amine derivative, (12Ser)2-
N12, 50–100 nm globular particles with high mass contrast, that
could indicate the presence of incorporated siRNA. With a (1:1)
MO content (Fig. 5B1), the particles seemingly increase in size
(roughly 100–500 nm) and have a more irregular shape. At higher
MO content (1:4), multilamellar structures, with clear sign of
siRNA compaction in the bilayers (Fig. 5C1, dark rims), are observ-
able. Moreover, some faceted bilayers are also clearly visible
(Fig. 5C10), with flat regions likely arising due to the polyanionic
RNA binding onto the net cationic surface. These micrographs also
show that the spheroidal particles seen by VELM in Fig. 3-C1, cor-
responding to the same sample as in Fig. 5C1, are indeed vesicular
structures.
In contrast to the amine system, the neat amide (12Ser)2CON12/
siRNA lipoplex system, i.e. without MO present (Fig. 5A2), already
shows the presence of vesicular structures, appearing faceted likely
due to the nucleic acid binding. When MO is added in a (1:1) ratio
(Fig. 5B2), 50–200 nm dark ill-defined nanoparticles are seen, sim-
ilar to what is observed for the amine at this composition. At (1:4)
ratio, 100–250 nm multilamellar vesicle structures are visible
(Fig. 5C2), with some of them showing densely compacted bilayers
due to siRNA binding (Fig. 5C20), just as for the amine system. This
type of structures correspond to typical multilamellar lipoplexes
previously reported for various systems [61,62]. The imaging thus
clearly shows that when present in high concentration, MO
induces the formation of 100–200 nm densely packed lipoplexes
with a multilamellar organization.
A study on the efficiency in siRNA complexation by the gemini/
MO aggregates was also conducted, using a sensitive, specific
nucleic acids stain (Ribogreen). This study allowed us to see some
differences between the three gemini surfactants, as shown in
Fig. 6. Aggregates containing (12Ser)2N12 or (12Ser)2COO12
become more effective in binding siRNA as the MO content41increases. This effect seems to be more pronounced for the amine
system. In contrast, the (12Ser)2CON12:MO aggregates showed the
same level of complexation efficiency irrespective of MO composi-
tion. Moreover, most systems reach maximal RNA complexation
ability (80–90%) between CR (+/-) of 5 and 10—with few excep-
tions, such as (12Ser)2N12:MO molar ratios (1:0), (4:1) and (2:1),
and neat ester surfactant.
3.5. Outlook and comparisons with previous studies
A number of reviews published in recent years have compre-
hensively dealt with the use of gemini surfactants as transfections
agents, alone or with helper lipids in assorted formulations
[6,29,63]. The role of spacer length and nature, tail length and
headgroup chemistry has been extensively studied, but direct com-
parisons looking for structure–function relationships can be
obscured using different nucleic acid molecules, transfection
strategies, cell lines and benchmarks. We will present the main
trends herein observed, possible interpretations and comparisons
with more directly related compounds and systems. The three
serine-based gemini surfactants investigated here form mixed bin-
ary aggregates with monoolein that are able to efficiently transfect
siRNA. The patterns presented by the different systems are some-
what complex, highlighting the role of headgroup chemical nature,
when both tail length and spacer length are fixed.
While MO induces some cytotoxicity effects in these mixtures,
contrarily to what we have observed with other cationic lipids
[54,64]— namely with respect to the neat amine and ester deriva-
tives, Table 1, less so with the amide one (possibly because this
surfactant per se already has a low IC50 value)— it is also clear that
MO content has a marked positive effect in the transfection ability
(Fig. 2). This is observed for all the three systems and is in line with
previous studies, where monovalent double-tailed surfactants
were used (e.g. DOBAB/DODAC) [53,54]. Lipoplexes with cationic
surfactant/RNA with CR (+/-) = 10 are particularly effective in the
case of the ester and amide derivatives (ca. 80% with respect to
Lipofectamine is attained), while for the amine derivative a CR
(+/-) = 5 is sufficient to attain the best possible efficiency (ca.
70%). Moreover, for the ester and amide derivatives, a CR
(+/-) = 5 is somewhat ineffective for transfection, irrespective of
Fig. 6. Complexation of siRNA by gemini:MO aggregates (total MO + surfactant
concentration is 1 mM) as a function of the CR (+/-).
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ing effect in liposomes constituted by DODAB (or DODAC) [54],
affecting liposomal internalization and resulting transfection effi-
ciency because of higher fusogenicity with the cell membrane.
The results of the current study suggest that such influence by
MO is observable in all three systems, although with differing
relevance.
In an effort to shed light on these results, in terms of the relation
between structure of the lipoplexes and transfection efficiency, we
also found that (i) addition of MO leads to the formation of mixed
vesicles in all three gemini surfactants, even in the case of the42amine surfactant (which only forms micelles per se); (ii) in partic-
ular, for the amide and ester derivatives, the mixed vesicles
become smaller and less polydisperse on increasing MO content;
(iii) lipoplexes with high MO content, (1:4), have a multilamellar
vesicle structure. In addition, the lipoplexes have sizes (<DH> ) in
the range 100–250 nm, as shown consistently by DLS and cryo-
TEM, and zeta potential values of about +40 mV.
Similar serine-based gemini surfactants have been used in our
group in transfections studies, but with a five-carbon spacer and
employing DOPE/cholesterol has helper lipid [36]. The surfactants
have also shown to be efficient in DNA compaction and transfec-
tion. Namely the ester derivative (12Ser)2COO5, reached 50% of
transfected HeLa cells at low CR (+/-) = 1 and 2. When compared
with Lipofectamine 2000, serine-based surfactants transfected
lower percentage of cells, but significantly they presented much
lower cytotoxicity [36], a known limitation of this commercially
available product. When comparing our current systems to lipo-
plexes formed by conventional bis-quaternary ammonium surfac-
tants [65], the lipoplexes containing serine-derived surfactants
present smaller sizes, compatible with intravenous administration,
which quickens load delivery to cells and tissues, and improves
drug bioavailability with low doses [66].
Summing up, the mixtures herein investigated constitute very
interesting lipofection vectors as their cytotoxicity profile is very
appropriate for biomedical use and offer good transfection efficien-
cies, which may be optimized in some conditions according to
siRNA load and helper lipid content. Transfection efficiency is
shown here in an experimental model with overexpression of
eGFP, by modification of the wild type cell line, so it is legitimate
to speculate that silencing a gene expressed in more physiological
levels will probably be more effective.4. Conclusions
Novel nanovectors were developed for siRNA delivery using
serine-derived gemini surfactants — (12Ser)2N12, amine deriva-
tive; (12Ser)2COO12, ester derivative; and (12Ser)2CON12, amide
derivative — and monoolein (MO) as helper lipid. Bearing in mind
the literature [6,29], our hypotheses were that the combination of
the gemini amino acid-based structure of the cationic amphiphiles
and a fusogenic lipid would result in innovative, effective transfec-
tion vectors, and that the gemini headgroup chemistry could also
play a relevant role.
We found that the addition of MO to the gemini surfactants
induces mixed vesicles, which typically become smaller and less
polydisperse on increasing MO content. The siRNA lipoplexes with
high MO content—gemini/MO molar ratio of (1:4)—have a multil-
amellar vesicle structure, and lipoplexes in general have mean
diameters of 100–250 nm, suitable for both intravenous adminis-
tration and effective transfection. Regarding RNA complexation,
most systems reach maximal values (80–90%) for charge ratios
(CR) (+/-) = 5–10. Although higher MO content typically favors
complexation, systems containing amine and ester gemini are
more dependent on lipid content for that than those with the
amide gemini. A key finding is that most compositions of the three
gemini/MO/siRNA systems lead to significant eGFP silencing, com-
parable to commercial standards, and without significant cytotox-
icity. While the amine-gemini:MO systems become more
transfection-efficient with increasing MO content irrespective of
CR (+/-), the ester and amide systems’ performance depends mark-
edly on charge ratio, the best one being CR (+/-) = 10. For the latter
systems, transfection efficiency either does not vary significantly
(ester case) or varies non-monotonically (amide case) with the
gemini:MO molar ratio. The final outcome is that the most effec-
tive systems are the amine-gemini:MO (1:4) at CR (+/-) = 5 or 10,
C. Costa, I.S. Oliveira, João P.N. Silva et al. Journal of Colloid and Interface Science 584 (2021) 34–44and the ester-gemini:MO (1:4) and amide-gemini:MO (1:1) both at
CR (+/-) = 10. The aggregate concentration for gene silencing does
not induce significant toxicity on human (HEK 293 T) cells.
Overall, it is shown that gemini serine-based surfactants and
monoolein combine indeed to yield robust and effective vectors
for siRNA transfection. The amine-gemini:MO systems are particu-
larly promising due to lower cytotoxicity and transfection effi-
ciency less dependent on charge ratio, yet further optimization
could be performed for all three systems. Our findings are thus a
contribution for the search of ever more efficient and safe non-
viral vectors for gene delivery.
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